Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. more
Time Frame | TXG | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.19% | 0.68% | 1.78% |
1-Month Return | -23.32% | -4.12% | -2.68% |
3-Month Return | -37.22% | 0.49% | 3.81% |
6-Month Return | -20.53% | 14.32% | 23.25% |
1-Year Return | -45.79% | 6.35% | 24.23% |
3-Year Return | -85.61% | 20.92% | 26.71% |
5-Year Return | -46.14% | 72.3% | 88.05% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 245.89M | 298.85M | 490.49M | 516.41M | 618.73M | [{"date":"2019-12-31","value":39.74,"profit":true},{"date":"2020-12-31","value":48.3,"profit":true},{"date":"2021-12-31","value":79.27,"profit":true},{"date":"2022-12-31","value":83.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 61.03M | 58.47M | 74.09M | 120.39M | 209.41M | [{"date":"2019-12-31","value":29.14,"profit":true},{"date":"2020-12-31","value":27.92,"profit":true},{"date":"2021-12-31","value":35.38,"profit":true},{"date":"2022-12-31","value":57.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 184.86M | 240.38M | 416.40M | 396.02M | 409.31M | [{"date":"2019-12-31","value":44.39,"profit":true},{"date":"2020-12-31","value":57.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.11,"profit":true},{"date":"2023-12-31","value":98.3,"profit":true}] |
Gross Margin | 75.18% | 80.44% | 84.89% | 76.69% | 66.15% | [{"date":"2019-12-31","value":88.56,"profit":true},{"date":"2020-12-31","value":94.75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.33,"profit":true},{"date":"2023-12-31","value":77.93,"profit":true}] |
Operating Expenses | 213.93M | 325.70M | 469.31M | 563.97M | 611.18M | [{"date":"2019-12-31","value":35,"profit":true},{"date":"2020-12-31","value":53.29,"profit":true},{"date":"2021-12-31","value":76.79,"profit":true},{"date":"2022-12-31","value":92.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (29.07M) | (85.32M) | (52.91M) | (167.94M) | (201.87M) | [{"date":"2019-12-31","value":-2907100000,"profit":false},{"date":"2020-12-31","value":-8532400000,"profit":false},{"date":"2021-12-31","value":-5291300000,"profit":false},{"date":"2022-12-31","value":-16794400000,"profit":false},{"date":"2023-12-31","value":-20186800000,"profit":false}] |
Total Non-Operating Income/Expense | (2.24M) | (449.30M) | (1.46M) | 12.14M | (30.02M) | [{"date":"2019-12-31","value":-18.41,"profit":false},{"date":"2020-12-31","value":-3699.79,"profit":false},{"date":"2021-12-31","value":-12.04,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-247.22,"profit":false}] |
Pre-Tax Income | (31.03M) | (534.48M) | (53.72M) | (161.97M) | (248.76M) | [{"date":"2019-12-31","value":-3103300000,"profit":false},{"date":"2020-12-31","value":-53447600000,"profit":false},{"date":"2021-12-31","value":-5371500000,"profit":false},{"date":"2022-12-31","value":-16197100000,"profit":false},{"date":"2023-12-31","value":-24876300000,"profit":false}] |
Income Taxes | 218.00K | 8.26M | 4.51M | 4.03M | 6.34M | [{"date":"2019-12-31","value":2.64,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":54.61,"profit":true},{"date":"2022-12-31","value":48.81,"profit":true},{"date":"2023-12-31","value":76.75,"profit":true}] |
Income After Taxes | (31.25M) | (542.73M) | (58.22M) | (166.00M) | (255.10M) | [{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}] |
Income From Continuous Operations | (31.25M) | (542.73M) | (58.22M) | (166.00M) | (255.10M) | [{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (31.25M) | (542.73M) | (58.22M) | (166.00M) | (255.10M) | [{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}] |
EPS (Diluted) | (0.56) | (5.13) | (0.52) | (1.47) | (2.17) | [{"date":"2019-12-31","value":-56,"profit":false},{"date":"2020-12-31","value":-513,"profit":false},{"date":"2021-12-31","value":-52,"profit":false},{"date":"2022-12-31","value":-147,"profit":false},{"date":"2023-12-31","value":-217,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TXG | |
---|---|
Cash Ratio | 3.06 |
Current Ratio | 4.69 |
Quick Ratio | 4.11 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TXG | |
---|---|
ROA (LTM) | -12.22% |
ROE (LTM) | -32.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TXG | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.23 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.77 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.30 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TXG | |
---|---|
Trailing PE | NM |
Forward PE | 196.08 |
P/S (TTM) | 6.65 |
P/B | 5.56 |
Price/FCF | 147 |
EV/R | 6.18 |
EV/Ebitda | NM |
PEG | 0.23 |
Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq:…
10x Genomics, Inc. announces the commercial availability of the Xenium Cell Segmentation Kit and the launch of the Xenium Immuno-Oncology Panel. The company aims to enhance single cell spatial analysis with advanced AI algorithms and diverse stains, catering to researchers'' needs for accurate cell segmentation and in-depth tumor microenvironment analysis.
In a significant advancement for the field of single cell and spatial biology, 10x Genomics, Inc. (Nasdaq: TXG) announced the launch of its first two products leveraging the groundbreaking GEM-X technology architecture. The products, named Chromium Single Cell Gene Expression 3′ v4 and Chromium Single Cell Immune Profiling 5′ v3, mark a pivotal moment in […]
The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime . Curing these diseases would be invaluable. The likelihood of that happening is something one can only dream of today. Yet based on research from Wood’s Ark Invest , the companies pursuing these treatments could see their enterprise value race higher by a 28% compounded annual growth rate. That means by the end of the decade their value would grow from $820 billion to $4.5 trillion! That could be why she is investing in the stocks of the biotechs utilizing CRISPR gene editing, RNA therapeutics and targeted protein degradation. Below are three top Cathie Wood biotech stocks to consider for your own portfolio. 10X Genomics (TXG) Source: Michael Vi / Shutterstock 10X Genomics (NASDAQ: TXG ) isn’t pursuing life-changing drug development itself but instead provides the tools researchers need to achieve their goals.
10X Genomics Inc at Stephens Investment Conference Transcript
Q3 2023 10X Genomics Inc Earnings Call Transcript
10X Genomics Inc (TXG) share price today is $28.4
Yes, Indians can buy shares of 10X Genomics Inc (TXG) on Vested. To buy 10X Genomics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TXG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of 10X Genomics Inc (TXG) via the Vested app. You can start investing in 10X Genomics Inc (TXG) with a minimum investment of $1.
You can invest in shares of 10X Genomics Inc (TXG) via Vested in three simple steps:
The 52-week high price of 10X Genomics Inc (TXG) is $63.57. The 52-week low price of 10X Genomics Inc (TXG) is $26.3.
The price-to-earnings (P/E) ratio of 10X Genomics Inc (TXG) is NM
The price-to-book (P/B) ratio of 10X Genomics Inc (TXG) is 5.56
The dividend yield of 10X Genomics Inc (TXG) is 0.00%
The market capitalization of 10X Genomics Inc (TXG) is $3.00B
The stock symbol (or ticker) of 10X Genomics Inc is TXG